If you or someone you care for takes thyroid medication, the prescription landscape is shifting under your feet. In August 2025, the FDA threatened enforcement action against manufacturers of desiccated thyroid extract products like Armour Thyroid and NP Thyroid, giving them until August 2026 to complete a formal approval process or face removal from the market. At the same time, a major recall pulled over 160,000 bottles of levothyroxine — the most commonly prescribed synthetic thyroid drug — off shelves due to subpotent tablets. For the millions of older adults managing hypothyroidism alongside cognitive decline or dementia risk, these disruptions are not abstract policy debates. They are immediate, practical problems.
This matters deeply for brain health. Thyroid hormones regulate metabolism in every organ, including the brain, and both undertreated and overtreated hypothyroidism have been linked to accelerated cognitive decline in older adults. New European guidelines published in 2025 estimate that nearly half of all treated hypothyroid patients worldwide are either under- or over-treated. That is a staggering number, and it suggests that the standard approach — prescribe levothyroxine, check TSH, move on — has been failing a large portion of patients for years. This article covers the FDA’s crackdown on natural thyroid products, the levothyroxine recall, emerging research on combination therapy, and what all of it means for people navigating thyroid treatment alongside dementia care.
Table of Contents
- Why Is New Research on Thyroid Meds Changing How Doctors Prescribe?
- The FDA’s Crackdown on Desiccated Thyroid Extract and What It Means for Patients
- The Levothyroxine Recall That Affected 160,000 Bottles
- Combination T4/T3 Therapy — A Practical Alternative Worth Discussing
- Why Thyroid Mismanagement Is Especially Dangerous for Brain Health
- What Caregivers Should Do Right Now
- Where Thyroid Treatment Is Heading
- Conclusion
- Frequently Asked Questions
Why Is New Research on Thyroid Meds Changing How Doctors Prescribe?
The short answer is that the old model — one drug, one lab value — is proving too blunt for too many patients. The European Thyroid Association’s 2025 guidelines on levothyroxine monotherapy acknowledged a problem that patients have reported for years: normal TSH numbers do not always mean a patient feels well or is optimally treated. A February 2025 study highlighted by the American Thyroid Association found that patients’ persistent symptoms on standard levothyroxine, despite technically “normal” lab results, are driving increasing research into alternative and combination treatments. Meanwhile, a meta-analysis of 11 clinical trials involving 1,135 patients found that 52 percent of patients preferred combination T4/T3 therapy or desiccated thyroid over levothyroxine alone.
Only 24 percent preferred monotherapy. The remaining 24 percent had no preference. Those numbers are hard to ignore, and they are pushing endocrinologists to reconsider whether levothyroxine monotherapy deserves its near-monopoly status in treatment guidelines. The Endocrine Society reported at ENDO 2023 that a growing number of hypothyroidism patients are already receiving treatments other than levothyroxine alone — a shift that is happening in practice even as official guidelines have been slow to catch up.
The FDA’s Crackdown on Desiccated Thyroid Extract and What It Means for Patients
On August 6 and 7, 2025, the FDA sent letters to manufacturers of desiccated thyroid extract products — including the well-known brands Armour Thyroid and NP Thyroid — warning that these animal-derived medications are technically “unapproved” and could face enforcement action. The FDA’s stated rationale centers on concerns about variations in purity, potency, and the presence of contaminants in these products. Manufacturers were given a 12-month transition period: by August 2026, any desiccated thyroid product that has not completed the FDA’s Biologics License Application process would become illegal to market and sell. As of early 2026, Armour Thyroid and NP Thyroid remain available, but the clock is ticking. CVS Caremark is already removing DTE medications including NP Thyroid from its standard formulary effective April 1, 2026, pushing patients toward synthetic alternatives.
For caregivers managing thyroid treatment in someone with dementia, this creates a real and urgent problem. Switching medications in a cognitively impaired person is not a simple pharmacy transaction. Dose equivalencies between desiccated thyroid and synthetic levothyroxine are imprecise, and any transition period carries the risk of under- or over-treatment — both of which can worsen confusion, fatigue, and cognitive symptoms. However, if the person you care for is stable on levothyroxine and has never taken desiccated thyroid, this particular disruption does not affect you directly. The FDA action targets only the animal-derived products. But it does reduce the menu of available options if levothyroxine alone proves inadequate down the road.
The Levothyroxine Recall That Affected 160,000 Bottles
Even the synthetic standard-bearer has had its problems. On July 14, 2025, the FDA issued a Class II recall for multiple strengths of levothyroxine sodium tablets manufactured by Intas Pharmaceuticals in India for Accord Healthcare, based in North Carolina. The reason: subpotent assay results, meaning the pills contained less active thyroid hormone than the label stated. The recall covered 160,630 bottles.
A separate Class II recall for Levoxyl, a branded levothyroxine product, was issued on August 8, 2025, by Pfizer — also due to subpotency. For an older adult with hypothyroidism and cognitive concerns, subpotent thyroid medication is a specific danger. If thyroid levels drift low because the pills are not delivering what they promise, the symptoms — brain fog, slowed thinking, fatigue, depression — can mimic or amplify dementia symptoms. A caregiver or clinician might attribute worsening cognition to the dementia progressing when the real culprit is an underdosed thyroid pill sitting in the medicine cabinet. This is why the ETA’s 2025 joint statement stressed that bioequivalence between formulations does not guarantee continued euthyroidism — patients may need retesting after any switch in brand, manufacturer, or formulation, even if the drug name on the label stays the same.
Combination T4/T3 Therapy — A Practical Alternative Worth Discussing
For patients who remain symptomatic on levothyroxine alone, combination therapy with both T4 (levothyroxine) and T3 (liothyronine) is gaining traction in research. The logic is straightforward: the thyroid gland naturally produces both hormones, and some patients — particularly those with genetic variations in the deiodinase enzymes that convert T4 to T3 — may not convert synthetic T4 efficiently enough to maintain adequate T3 levels in the brain and other tissues. Personalized dosing research using the p-THYROSIM computational model has attempted to define optimal daily combination doses: roughly 5 to 7.5 micrograms of T3 plus 62.5 to 100 micrograms of T4 for women, or 75 to 125 micrograms of T4 alone for men. A new randomized controlled trial launched in 2025 is testing slow-release liothyronine combined with levothyroxine in 100 hypothyroid patients, with the hypothesis that this approach can restore T3 levels for patients who have persistent symptoms despite normal TSH.
The tradeoff is real, though. Liothyronine has a short half-life, which means blood levels of T3 can spike and drop throughout the day. In older adults, those spikes can increase heart rate and raise the risk of atrial fibrillation — a serious concern for anyone already at cardiovascular risk. The slow-release formulation being tested in the 2025 trial may solve this problem, but it is not yet widely available. Standard immediate-release liothyronine requires careful dosing and monitoring, and not every physician is comfortable prescribing it.
Why Thyroid Mismanagement Is Especially Dangerous for Brain Health
The connection between thyroid function and cognition is well established, and the margin for error is narrow in older adults. Undertreated hypothyroidism can cause symptoms that look remarkably like early dementia: slowed processing speed, impaired short-term memory, difficulty concentrating, and depression. Overtreated hypothyroidism — too much thyroid hormone — carries its own cognitive risks, along with bone loss and cardiac arrhythmias. The ETA’s 2025 guidelines highlight an uncomfortable reality: nearly half of treated hypothyroid patients worldwide appear to be under- or over-treated when using serum TSH as the sole marker.
For a person with Alzheimer’s disease or another form of dementia, this margin of error becomes even more consequential because they may not be able to articulate new or worsening symptoms. A person with dementia is unlikely to say, “I feel more fatigued than usual and my thinking seems foggier since the pharmacy switched my thyroid brand.” That burden falls entirely on caregivers and clinicians, which is why proactive monitoring — not just reactive symptom management — is essential. One limitation worth noting: most thyroid-cognition research has been conducted in cognitively healthy older adults, not in people already diagnosed with dementia. The assumption that optimal thyroid treatment improves cognition in dementia patients is reasonable but not yet proven with the rigor that evidence-based medicine demands.
What Caregivers Should Do Right Now
If you are a caregiver for someone taking thyroid medication, check the brand and manufacturer on the current prescription bottle. If it is a desiccated thyroid product like Armour Thyroid or NP Thyroid, contact the prescribing physician now — not in August 2026 when these products may disappear from pharmacy shelves. Rushed transitions lead to dosing errors. A planned, monitored switch with follow-up lab work in six to eight weeks gives the best chance of maintaining stable thyroid levels.
If the person is taking generic levothyroxine, verify the manufacturer against the recall lists. Intas Pharmaceuticals and Pfizer’s Levoxyl product were both subject to recalls in mid-2025. Ask the pharmacist to confirm the current supply is not from affected lots, and request consistent dispensing of the same manufacturer’s product at every refill. Brand switching at the pharmacy level — which happens routinely based on supply contracts — can quietly destabilize a patient whose thyroid levels were well-controlled.
Where Thyroid Treatment Is Heading
The direction is clear, even if the pace is slow: thyroid treatment is moving toward greater personalization. The one-size-fits-all levothyroxine-and-TSH model is being challenged by patient preference data, combination therapy trials, computational dosing models, and new guidelines that acknowledge the limitations of TSH as a sole marker. The 2025 slow-release T3 trial, if successful, could provide a safer option for combination therapy that avoids the hormone spikes of current liothyronine formulations.
For brain health specifically, the hope is that more precise thyroid management — getting the right hormones to the right tissues at the right levels — will translate into measurable cognitive benefits, particularly in vulnerable older adults. That research is still developing, but the foundation is being laid. In the meantime, the most important thing caregivers and patients can do is stay informed about the medications currently in the medicine cabinet and make sure no one is left scrambling when the regulatory and formulary changes take full effect in mid-2026.
Conclusion
Thyroid treatment in 2025 and 2026 is in genuine flux. The FDA’s move against desiccated thyroid products, the levothyroxine recall, new European guidelines acknowledging widespread under- and over-treatment, and growing evidence for combination therapy are collectively reshaping how doctors think about hypothyroidism management. For people caring for someone with dementia or cognitive decline, the stakes of getting thyroid treatment right are higher than for the general population — and the current disruptions make that more difficult, not less.
The practical steps are concrete: verify current medications against recall lists, plan ahead for the possible loss of desiccated thyroid products, request consistent brand dispensing at the pharmacy, and push for follow-up lab work after any medication change. Do not wait for a crisis. Thyroid hormones are slow-moving — it takes weeks for the effects of a dose change to fully manifest — and by the time symptoms appear, the window for a smooth correction has already narrowed.
Frequently Asked Questions
Will Armour Thyroid be completely unavailable after August 2026?
If the manufacturer does not complete the FDA’s Biologics License Application process by August 2026, Armour Thyroid would become illegal to market and sell in the United States. As of early 2026, it remains available, but patients should plan for the possibility that it will be removed from the market.
Was my levothyroxine affected by the 2025 recall?
The July 2025 recall covered 160,630 bottles of levothyroxine sodium tablets manufactured by Intas Pharmaceuticals for Accord Healthcare. A separate recall in August 2025 affected Pfizer’s Levoxyl tablets. Check the manufacturer name on your prescription bottle and consult the FDA’s recall database or your pharmacist to verify whether your specific lot was affected.
Can combination T4/T3 therapy help with brain fog from hypothyroidism?
Research suggests that some patients — particularly those who remain symptomatic on levothyroxine alone — may benefit from combination therapy. A meta-analysis of 11 trials found that 52 percent of patients preferred combination therapy over monotherapy. However, T3 supplementation carries cardiovascular risks, especially in older adults, and should only be initiated under medical supervision with careful monitoring.
Does switching thyroid medication brands matter?
Yes. The European Thyroid Association’s 2025 joint statement emphasized that bioequivalence between formulations does not guarantee that a patient will remain optimally treated after switching brands or manufacturers. Retesting thyroid levels six to eight weeks after any brand change is recommended.
How does undertreated hypothyroidism affect dementia?
Undertreated hypothyroidism can cause cognitive symptoms — slowed thinking, memory problems, fatigue, depression — that mimic or worsen dementia. The ETA’s 2025 guidelines estimate that nearly half of treated hypothyroid patients worldwide are under- or over-treated, which is especially concerning for older adults with existing cognitive impairment who may not be able to report worsening symptoms.
